Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases

Current antibiotics tend to be broad spectrum, leading to indiscriminate killing of commensal bacteria and accelerated evolution of drug resistance. Here, we use CRISPR-Cas technology to create antimicrobials whose spectrum of activity is chosen by design. RNA-guided nucleases (RGNs) targeting specific DNA sequences are delivered efficiently to microbial populations using bacteriophage or bacteria carrying plasmids transmissible by conjugation. The DNA targets of RGNs can be undesirable genes or polymorphisms, including antibiotic resistance and virulence determinants in carbapenem-resistant Enterobacteriaceae and enterohemorrhagic Escherichia coli. Delivery of RGNs significantly improves survival in a Galleria mellonella infection model. We also show that RGNs enable modulation of complex bacterial populations by selective knockdown of targeted strains based on genetic signatures. RGNs constitute a class of highly discriminatory, customizable antimicrobials that enact selective pressure at the DNA level to reduce the prevalence of undesired genes, minimize off-target effects and enable programmable remodeling of microbiota.

[1]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[2]  R. Miller,et al.  One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Jacoby.  Mechanisms of resistance to quinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Finbarr Hayes,et al.  Toxins-Antitoxins: Plasmid Maintenance, Programmed Cell Death, and Cell Cycle Arrest , 2003, Science.

[5]  P. Pavlík,et al.  Eliminating helper phage from phage display , 2006, Nucleic acids research.

[6]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[7]  John C March,et al.  Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model , 2010, Proceedings of the National Academy of Sciences.

[8]  George M Church,et al.  Concerning RNA-guided gene drives for the alteration of wild populations , 2014, bioRxiv.

[9]  Daniel Mucida,et al.  CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. , 2012, Cell host & microbe.

[10]  E. Denamur,et al.  Molecular characterization of addiction systems of plasmids encoding extended-spectrum beta-lactamases in Escherichia coli. , 2010, The Journal of antimicrobial chemotherapy.

[11]  S. Rosenberg,et al.  Spontaneous DNA breakage in single living Escherichia coli cells , 2007, Nature Genetics.

[12]  J. Keasling,et al.  High-level semi-synthetic production of the potent antimalarial artemisinin , 2013, Nature.

[13]  Philippe Horvath,et al.  The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA , 2010, Nature.

[14]  P. Nordmann,et al.  Carbapenem resistance in Enterobacteriaceae: here is the storm! , 2012, Trends in molecular medicine.

[15]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[16]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[17]  J. Dolan,et al.  Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections , 2003, Antimicrobial Agents and Chemotherapy.

[18]  J. Vogel,et al.  CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III , 2011, Nature.

[19]  Timothy K Lu,et al.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy , 2009, Proceedings of the National Academy of Sciences.

[20]  Fernando de la Cruz,et al.  Escherichia coli genes affecting recipient ability in plasmid conjugation: Are there any? , 2009, BMC Genomics.

[21]  Feng Zhang,et al.  CRISPR-assisted editing of bacterial genomes , 2013, Nature Biotechnology.

[22]  Peter C. Fineran,et al.  Cytotoxic Chromosomal Targeting by CRISPR/Cas Systems Can Reshape Bacterial Genomes and Expel or Remodel Pathogenicity Islands , 2013, PLoS genetics.

[23]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[24]  R. Humphries,et al.  New Delhi Metallo-β-Lactamase–producing Enterobacteriaceae, United States , 2013, Emerging infectious diseases.

[25]  Chase L. Beisel,et al.  Programmable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems , 2014, mBio.

[26]  H. Bujard,et al.  Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. , 1997, Nucleic acids research.

[27]  Andrew Camilli,et al.  A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity , 2013, Nature.

[28]  P. Coote,et al.  Utility of Greater Wax Moth Larva (Galleria mellonella) for Evaluating the Toxicity and Efficacy of New Antimicrobial Agents. , 2012, Advances in applied microbiology.

[29]  Harry L. T. Mobley,et al.  Pathogenic Escherichia coli , 2004, Nature Reviews Microbiology.

[30]  James J. Collins,et al.  Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.

[31]  G. Jacoby,et al.  Characterization of the Extended-Spectrum β-Lactamase Reference Strain, Klebsiella pneumoniae K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18 , 2000, Antimicrobial Agents and Chemotherapy.

[32]  N. Friedman,et al.  Reversing Bacterial Resistance to Antibiotics by Phage-Mediated Delivery of Dominant Sensitive Genes , 2011, Applied and Environmental Microbiology.

[33]  Boris Hayete,et al.  Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli , 2007 .

[34]  N. Costantino,et al.  A set of recombineering plasmids for gram-negative bacteria. , 2006, Gene.

[35]  A simple and rapid method to isolate purer M13 phage by isoelectric precipitation , 2013, Applied Microbiology and Biotechnology.

[36]  M. Fischbach,et al.  Community Health Care: Therapeutic Opportunities in the Human Microbiome , 2011, Science Translational Medicine.

[37]  C. Nielsen-Leroux,et al.  The insect Galleria mellonella as a powerful infection model to investigate bacterial pathogenesis. , 2012, Journal of visualized experiments : JoVE.

[38]  R. Sikorski,et al.  A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. , 1989, Genetics.

[39]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[40]  P. Hergenrother,et al.  Artificial activation of toxin-antitoxin systems as an antibacterial strategy. , 2012, Trends in microbiology.